Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications

15 Sept 2012

Abstract excerpt

The next-generation ophthalmic anti-VEGF therapeutics must aim at being superior to the currently available agents with regard to potency and improved drug delivery, while still being stable and safe to use at elevated concentrations. We show here the generation of a set of highly potent VEGF-A antagonistic DARPins (designed ankyrin repeat proteins) delivering these properties. DARPins with single-digit picomolar...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Retinal and Macular Surgery
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22983424
DOI: 10.1007/s10456-012-9302-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applicationsPMID 22983424Read ↗

GB10, a best-in-class antibody fusion protein targeting VEGF/Ang-2, exhibits promising therapeutic efficacy for neovascular eye diseasesSemantic proximity Read ↗

A Decade of Clinical Experience with DARPins in Oncology and Virology: A Systematic ReviewSemantic proximity Read ↗

Anti-Human VEGF Repebody Effectively Suppresses Choroidal Neovascularization and Vascular Leakage.Semantic proximity Read ↗

Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and TherapySemantic proximity Read ↗

Engineered RPE Cell Therapy for Controllable Anti-VEGF Delivery in Neovascular AMDSemantic proximity Read ↗

The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal diseaseSemantic proximity Read ↗

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in OphthalmologySemantic proximity Read ↗

Targeting vascular endothelial growth factor using retinal gene therapySemantic proximity Read ↗

Thrombospondin-1 proteomimetic polymers exhibit anti-angiogenic activity in a neovascular age-related macular degeneration mouse modelSemantic proximity Read ↗

Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and BeyondSemantic proximity Read ↗

Designed Ankyrin Repeat Proteins: A New Class of Viral Entry InhibitorsSemantic proximity Read ↗

Transcriptome Profiling of Neovascularized Corneas Reveals miR-204 as a Multi-target Biotherapy Deliverable by rAAVsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.